Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chickenpox01:20

Chickenpox

Chickenpox is an acute, highly contagious disease caused by the varicella-zoster virus (VZV), a double-stranded DNA virus belonging to the Herpesviridae family. Its transmission occurs primarily through the inhalation of respiratory droplets or direct contact with vesicular fluid from skin lesions. The incubation period typically ranges from 10 to 21 days, during which the virus replicates and disseminates through sequential phases within the host. Although generally self-limiting in children,...
Vaccinations01:51

Vaccinations

Overview
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Cross-reactivity00:42

Cross-reactivity

Overview
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exosomes in Dermatology.

Skin therapy letter·2026
Same author

Enhanced Home-Based Wart Treatment Protocol: Optimizing Debridement and Occlusion Therapy for Improved Outcomes.

Advances in skin & wound care·2026
Same author

Herpes Zoster Risk in the Era of Targeted Immunotherapy: JAK Inhibitors Versus Biologics.

Journal of cutaneous medicine and surgery·2026
Same author

Acquired Epidermodysplasia Verruciformis in Patients with Iatrogenic Immunosuppression.

Journal of clinical medicine·2026
Same author

A novel oral interleukin-23 receptor antagonist peptide, icotrokinra, for moderate-to- severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.

Inflammopharmacology·2026
Same author

Nemolizumab as an Alternative Therapeutic Option for Indolent Systemic Mastocytosis.

Cureus·2026
Same journal

Biologic modulation of ineffective erythropoiesis in thalassemia: mechanisms, clinical practice, and future targets.

Expert opinion on biological therapy·2026
Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026
Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026
Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026
Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026
Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

Shingles vaccine.

C Beau Willison1, L Katie Morrison, Natalia Mendoza

  • 1Center for Clinical Studies, 451 North Texas Avenue, Webster, Texas 77598, USA. bwillison@ccstexas.com

Expert Opinion on Biological Therapy
|February 2, 2010
PubMed
Summary
This summary is machine-generated.

The live attenuated zoster vaccine effectively prevents shingles in adults aged 60 and older. This vaccine is well-tolerated and recommended for preventing debilitating herpes zoster complications.

More Related Videos

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

Related Experiment Videos

Last Updated: Jun 16, 2026

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

Area of Science:

  • Virology
  • Immunology
  • Preventive Medicine

Background:

  • Herpes zoster (shingles) is a debilitating condition affecting 10-30% of the population.
  • Previously, only treatments to manage symptoms existed, lacking preventive options for immunocompetent adults.
  • The live attenuated zoster vaccine (Zostavax) is now available and recommended for prevention.

Purpose of the Study:

  • To review the development and current status of the live attenuated zoster vaccine.
  • To provide comprehensive information on zoster vaccination strategies.

Main Methods:

  • A literature review covering the live attenuated zoster vaccine from the 1970s to the present.
  • Analysis of vaccine pharmacology, efficacy, and safety data.

Main Results:

  • The live attenuated zoster vaccine is effective in preventing shingles in individuals aged 60 and above.
  • The vaccine is well-tolerated and recommended by the CDC's Advisory Committee for Immunization Practices.

Conclusions:

  • The live attenuated zoster vaccine offers an effective and safe method for preventing zoster and its sequelae.
  • It is recommended for immunocompetent individuals aged 60 years and older.
  • Research continues to explore new prevention methods for zoster.